

MSD and NHS in collaboration: Working together to support chemotherapy infusion suites with capacity challenges



Capacity challenges in the administration of intravenous chemotherapy

NHS hospital trusts are facing challenges in the administration of cancer treatments in their chemotherapy infusion suites potentially due to:



**Increasing patient
numbers compared with
current demand¹**



**New treatments
becoming available²**



**Staff
sickness³**



**Unfilled
vacancies³**

This inability to meet the demand for treatment administration may have a negative effect on patients' health,⁴ which may further affect their eligibility for some treatment regimens and could lead to a breach in cancer treatment targets.⁵

How can MSD help optimise current capacity and service efficiency within NHS hospital trusts?

MSD have a healthcare team dedicated to:

- Understanding the current demands of chemotherapy infusion suites
- Facilitating conversations and workshops
- Modelling scenarios to explore potential solutions

MSD have created a capacity insights tool to help identify and model the demands of local cancer treatment services, enabling NHS hospital trusts to adjust various parameters to visualise the impact of current and future demands.

**MSD healthcare
team discusses
efficiency and capacity
challenges within
the NHS**

**Current
chemotherapy
infusion suite
parameters are
captured and
future changes
modelled**

**MSD generates
a follow-up
report**

**MSD discusses
outputs with the
NHS team**

**MSD are committed to working in partnership with the NHS to enhance current capacity and service delivery.
Please use the contact details below to arrange a discussion with a member of the healthcare team.**



msdukhealthcare@msd.com

References: 1. NHS England. NHS diagnoses thousands more cancers as cases rise by 5%. Available at: <https://www.england.nhs.uk/2024/10/nhs-diagnoses-thousands-more-cancers-as-cases-rise-by-5/>. Accessed: July 2025. 2. Navigating Cancer. The Emerging Challenges in Cancer Care. Available at: www.navigatingcancer.com/the-emerging-challenges-in-cancer-care. Accessed: July 2025. 3. Ham C. *BMJ* 2021;375:2587. 4. Hanna T, et al. *BMJ* 2020;371:4087. 5. My HSN. What are the 31 and 62 day NHS cancer targets? Available at: <https://www.myhsn.co.uk/top-tip/what-are-the-31-and-62-day-nhs-cancer-targets/>. Accessed: July 2025.

GB-NON-11623 | July 2025
Copyright © 2025 Merck & Co. Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Merck Sharp & Dohme (UK) Limited.
120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687.